throbber
Page 1
`
`IN THE UNITED STATES DISTRICT COURT
`
`FOR THE DISTRICT OF NEW JERSEY
`
`JANSSEN R&D IRELAND, et al.,
`
`)
`
`Plaintiffs,
`
`) Consolidated Civil
`
`vs.
`
`) Action No. 10-5954
`
`LUPIN LIMITED, et al.,
`
`Defendants.
`
`(WHW)
`
`(CLW)
`
`)
`
`)
`
`The videotaped deposition of GARLAND R.
`
`MARSHALL, Ph.D., called for examination,
`
`taken
`
`pursuant to the Federal Rules of Civil Procedure of
`
`the United States District Courts pertaining to the
`
`taking of depositions,
`
`taken before Lynn A. McCauley,
`
`CSR No. 84—003268, RPR, a Certified Shorthand
`
`Reporter of the State of Illinois, at 6 West Hubbard
`
`Street, Suite 500, Chicago, Illinois, on October 22,
`
`2013, at 9:08 a.m.
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`212-267-6868
`
`wnVwnVerfieXLcon1
`
`516-608-2400
`
`VERHEXTREPOKHNGCONWANY
`
`Janssen Ex. 2045
`
`Lupin Ltd. v. Janssen Sciences Ireland UC
`|PR201501030
`
`(Page1 of11)
`
`

`
`BY MS. ROYZMAN:
`
`Page 115
`
`11:39:22
`
`Q.
`
`Let me hand you as Marshall Exhibit 9 the
`
`11:39:22
`
`Searle '775 patent.
`
`11:39:27
`
`You've seen this document before,
`
`11:39:32
`
`Dr. Marshall?
`
`11:39:33
`
`11:39:34
`
`Yes,
`
`I have.
`
`A.
`
`Q.
`
`Darunavir is disclosed in Table 16K of
`
`11:39:35
`
`the '775 patent; is that right?
`
`A.
`
`I'll have to look at Table 16?
`
`Q.
`
`A.
`
`16K.
`
`15K.
`
`11:39:54
`
`11:39:57
`
`11:40:01
`
`11:40:09
`
`Q.
`
`Sorry.
`
`16K. Columns 161, 162.
`
`11:40:11
`
`Do you have that?
`
`11:40:19
`
`A.
`
`I'm —— I'm searching for the structure.
`
`11:40:20
`
`11:40:26
`
`Q.
`
`It's Columns 161, 162 on the top if that
`
`11:40:26
`
`A.
`
`Thank you. There's a lot of different
`
`11:40:31
`
`11:40:34
`
`Q.
`
`There are a lot of sulfonamide HIV
`
`11:40:40
`
`11:40:31
`
`16K.
`
`helps.
`
`tables.
`
`protease inhibitors disclosed in the '775 patent; is
`
`11:40:44
`
`that right?
`
`A. Definitely.
`
`11:40:49
`
`11:40:49
`
`MS. BRODY:
`
`I'm sorry. Did you withdraw the
`
`11:40:53
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`212-267-6868
`
`wWw.VeriteXt.com
`
`516-608-2400
`
`VERITEXT REPORTING COMPANY
`
`Janssen Ex. 2045
`
`Lupin Ltd. v. Janssen Sciences Ireland UC
`|PR2015-01030
`
`(Page 2 of 11)
`
`

`
`prior question then?
`
`THE WITNESS:
`
`I don't ——
`
`Page 116
`
`11:40:55
`
`11:40:57
`
`MS. BRODY:
`
`Just one second.
`
`I'm just —— you
`
`11:40:58
`
`asked two questions.
`
`BY MS. ROYZMAN:
`
`11:40:59
`
`11:41:01
`
`Q.
`
`Dr. Marshall,
`
`there are thousands of HIV
`
`11:41:05
`
`protease inhibitors disclosed in the '775 patent; is
`
`11:41:09
`
`that right?
`
`MS. BRODY: Objection to the form.
`
`BY THE WITNESS:
`
`11:41:13
`
`11:41:13
`
`11:41:14
`
`A.
`
`Inhibitors disclosed.
`
`There are lots of
`
`11:41:17
`
`compounds which were described.
`
`11:41:20
`
`How many are disclosed in terms of
`
`11:41:22
`
`their affinity for the receptor,
`
`their in vitro
`
`11:41:24
`
`activity and so on,
`
`I don't remember, but it's a
`
`11:41:28
`
`common practice for patents to describe literally
`
`11:41:32
`
`thousands to millions of compounds for which only a
`
`11:41:37
`
`few examples are given, and I assume that's the case
`
`11:41:41
`
`for this as well.
`
`11:41:44
`
`I happen to know the people who
`
`11:41:45
`
`worked on this project,
`
`this project migrated from my
`
`11:41:47
`
`lab to the people at Searle, so I know they made a
`
`11:41:52
`
`lot of sulfonamides,
`
`I can agree with that.
`
`11:41:55
`
`Although I was just looking at 16K,
`
`11:41:58
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`212-267-6868
`
`wWw.VeriteXt.com
`
`516-608-2400
`
`VERITEXT REPORTING COMPANY
`
`Janssen Ex. 2045
`
`Lupin Ltd. v. Janssen Sciences Ireland UC
`|PR2015-01030
`
`(Page 3 of 11)
`
`

`
`Page 117
`
`and I was trying to find a structure of darunavir and
`
`11:42:00
`
`I don't see it there.
`
`Q.
`
`16K, Columns 161, 162?
`
`11:42:03
`
`11:42:10
`
`A. Well,
`
`they left out an oxygen.
`
`11:42:16
`
`Q.
`
`Yeah,
`
`there's —— there's some overlay
`
`11:42:19
`
`issues in ——
`
`11:42:22
`
`A.
`
`Okay. Well,
`
`I'm just saying if I look at
`
`11:42:23
`
`this column,
`
`that is not the structure of bis—THF, so
`
`11:42:25
`
`I mean it —— it may have been corrected, but in the
`
`11:42:32
`
`document I have, 161 on the bottom left —— I mean if
`
`11:42:35
`
`I go back —— if I go back to Column 219,
`
`then bis—THF
`
`11:43:05
`
`is certainly shown correctly.
`
`Q.
`
`A.
`
`Q.
`
`A.
`
`Column 219 is ——
`
`Yeah.
`
`—— the Claims?
`
`Or 221, yes.
`
`11:43:12
`
`11:43:13
`
`11:43:15
`
`11:43:16
`
`11:43:16
`
`(Whereupon, a certain
`
`document was marked
`
`Marshall No. 10 for
`
`identification.)
`
`BY MS. ROYZMAN:
`
`11:43:18
`
`Q.
`
`Just to keep the record clear, let me
`
`11:43:18
`
`hand you as Marshall Exhibit 10, WO 95/06030 which is
`
`11:43:28
`
`the PCT counterpart of this application.
`
`11:43:37
`
`212-267-6868
`
`wWw.VeriteXt.com
`
`516-608-2400
`
`VERITEXT REPORTING COMPANY
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`Janssen Ex. 2045
`
`Lupin Ltd. v. Janssen Sciences Ireland UC
`|PR2015-01030
`
`(Page 4 of 11)
`
`

`
`You've seen this document before,
`
`11:43:47
`
`Dr. Marshall?
`
`11:43:49
`
`A.
`
`In all candor,
`
`I probably have, but I do
`
`11:43:58
`
`Page 118
`
`not remember it.
`
`11:44:00
`
`11:44:03
`
`Okay.
`
`Q.
`
`A.
`
`Normally what's covered in European
`
`11:44:03
`
`patents is a —— essentially the same as covered in
`
`11:44:06
`
`American patents, so if I saw it, I'm not so sure I
`
`11:44:10
`
`reviewed it in any great detail since I reviewed the
`
`11:44:13
`
`American Searle patent.
`
`11:44:17
`
`Q.
`
`Let's turn to Table 16K that's —— that's
`
`11:44:18
`
`Page 204 on top.
`
`11:44:22
`
`A.
`
`On that Table 16K the correct structure
`
`11:44:33
`
`of bis—THF is shown.
`
`11:44:38
`
`Q.
`
`Okay. And so darunavir is disclosed in
`
`11:44:40
`
`Table 16K of Searle's patent; correct?
`
`A.
`
`Yes.
`
`11:44:42
`
`11:44:45
`
`Q.
`
`The '775 patent doesn't provide any data
`
`11:44:46
`
`for darunavir; is that right?
`
`MS. BRODY: Objection to the form.
`
`BY THE WITNESS:
`
`11:44:59
`
`11:45:00
`
`11:45:01
`
`A.
`
`That's —— that's my understanding.
`
`11:45:01
`
`BY MS. ROYZMAN:
`
`11:45:03
`
`Q.
`
`The '775 patent does provide data for
`
`11:45:03
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`212-267-6868
`
`wWw.VeriteXt.com
`
`516-608-2400
`
`VERITEXT REPORTING COMPANY
`
`Janssen Ex. 2045
`
`Lupin Ltd. v. Janssen Sciences Ireland UC
`|PR2015-01030
`
`(Page 5 of 11)
`
`

`
`other HIV protease inhibitors; correct?
`
`MS. BRODY: Objection to the form.
`
`BY THE WITNESS:
`
`A.
`
`That's true.
`
`BY MS. ROYZMAN:
`
`Page 119
`
`11:45:07
`
`11:45:10
`
`11:45:11
`
`11:45:11
`
`11:45:15
`
`Q.
`
`Now, I'd like to turn to Paragraph 32 of
`
`11:45:16
`
`your opening expert report.
`
`11:45:27
`
`In Paragraph 32 on Page 10 of your
`
`11:45:49
`
`opening expert report you state,
`
`"The '775 patent
`
`11:45:52
`
`also gives no indication that the claim compound
`
`11:45:56
`
`darunavir would have any utility as a protease
`
`11:46:00
`
`inhibitor or otherwise."
`
`Do you see that?
`
`A.
`
`I do.
`
`11:46:07
`
`11:46:08
`
`11:46:08
`
`Q.
`
`A.
`
`patent.
`
`Do you stand by that statement?
`
`11:46:09
`
`I stand by that statement for the '775
`
`11:46:10
`
`11:46:13
`
`Q.
`
`Is it your opinion that a person of
`
`11:46:13
`
`ordinary skill in the art would select darunavir for
`
`11:46:16
`
`further drug development based on the '775 patent?
`
`11:46:20
`
`A.
`
`In 1994 the answer is no.
`
`11:46:26
`
`Q.
`
`Is there a timeframe in which that answer
`
`11:46:29
`
`changes?
`
`A.
`
`I would think so.
`
`11:46:47
`
`11:46:47
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`212-267-6868
`
`wWw.VeriteXt.com
`
`516-608-2400
`
`VERITEXT REPORTING COMPANY
`
`Janssen Ex. 2045
`
`Lupin Ltd. v. Janssen Sciences Ireland UC
`|PR2015-01030
`
`(Page 6 of 11)
`
`

`
`Q.
`
`When is that?
`
`Page 120
`
`11:46:48
`
`A.
`
`I would suspect by the '98 patent —— or
`
`11:46:49
`
`the '98 paper of Ghosh and subsequent patents that
`
`11:46:52
`
`would have changed people's attitude about darunavir.
`
`11:46:57
`
`Q. What subsequent patents?
`
`11:47:00
`
`A.
`
`It could be the Tibotec patent.
`
`11:47:03
`
`I don't —— but, no,
`
`I mean,
`
`11:47:06
`
`subsequent patent.
`
`There was one, and I don't
`
`11:47:08
`
`remember the number,
`
`that I think came out of NIH
`
`11:47:12
`
`with various people on the patent; and, again, I'd
`
`11:47:15
`
`have to look it up and tell you the number because I
`
`11:47:20
`
`don't recall it.
`
`11:47:22
`
`Q.
`
`A.
`
`Q.
`
`You're referring to the NIH '506 patent?
`
`11:47:23
`
`I suspect that's the number, yes.
`
`11:47:26
`
`Okay.
`
`So you're —— you're not saying
`
`11:47:28
`
`that based on the '775 patent alone that darunavir
`
`11:47:33
`
`would be a compound of interest for drug development;
`
`11:47:40
`
`correct?
`
`11:47:48
`
`MS. BRODY: Objection to the extent it
`
`11:47:48
`
`mischaracterizes the witness's testimony and the
`
`11:47:50
`
`opinion set forth in his expert report at Marshall
`
`11:47:53
`
`Exhibit 6 and in his reply report.
`
`BY THE WITNESS:
`
`11:47:56
`
`11:47:58
`
`A.
`
`I —— I would think that anybody that was
`
`11:47:58
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`212-267-6868
`
`wWw.VeriteXt.com
`
`516-608-2400
`
`VERITEXT REPORTING COMPANY
`
`Janssen Ex. 2045
`
`Lupin Ltd. v. Janssen Sciences Ireland UC
`|PR2015-01030
`
`(Page 7 of 11)
`
`

`
`However, as someone who has done
`
`12:04:11
`
`Page 133
`
`assays on biological systems and taught pharmacology,
`
`12:04:15
`
`data without error bars —— he shows error bars for
`
`12:04:20
`
`14, which is 1.1 plus or minus 0.4.
`
`12:04:24
`
`There are no error bars given for
`
`12:04:28
`
`Compound 13,
`
`therefore,
`
`I don't know whether there's
`
`12:04:30
`
`any significant difference in those measured numbers
`
`12:04:33
`
`or not.
`
`12:04:36
`
`You know, again,
`
`I had been the
`
`12:04:36
`
`editor for this journal,
`
`I would have asked for more
`
`12:04:38
`
`data.
`
`BY MS. ROYZMAN:
`
`12:04:41
`
`12:04:43
`
`Q.
`
`Okay. Dr. Ghosh in his 1998 article
`
`12:04:44
`
`says, again, 4—methoxybenzene —— benzenesulfonamide
`
`12:04:49
`
`is more potent than the 4—aminobenzenesulfonamide 13
`
`12:04:55
`
`or the toluenesulfonamide 15.
`
`12:05:01
`
`12:05:05
`
`12:05:06
`
`Do you see that?
`
`Yes,
`
`I do.
`
`A.
`
`Q.
`
`And he describes Compound 14, which is
`
`12:05:07
`
`the methoxy compound, as an extremely potent
`
`12:05:12
`
`inhibitor; correct?
`
`12:05:15
`
`A.
`
`Yes. And that —— and based on the same
`
`12:05:18
`
`data,
`
`I would say Compound 13 is an extremely potent
`
`12:05:20
`
`inhibitor.
`
`12:05:24
`
`212-267-6868
`
`wWw.VeriteXt.com
`
`516-608-2400
`
`VERITEXT REPORTING COMPANY
`
`Janssen Ex. 2045
`
`Lupin Ltd. v. Janssen Sciences Ireland UC
`|PR2015-01030
`
`(Page 8 of 11)
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`

`
`BY MS. ROYZMAN:
`
`Page 134
`
`12:05:25
`
`Q.
`
`Now, Dr. Ghosh, however, says that
`
`12:05:25
`
`Compound 14, which is the methoxy compound is more
`
`12:05:32
`
`potent than the 4—aminobenzenesulfonamide, Compound
`
`12:05:39
`
`13, or the toluenesulfonamide; correct?
`
`12:05:46
`
`MS. BRODY: Objection to the form. Asked and
`
`12:05:51
`
`answered. Objection to the extent it
`
`mischaracterizes the document.
`
`BY THE WITNESS:
`
`12:05:52
`
`12:05:53
`
`12:05:55
`
`A.
`
`I have no, you know, comment on how
`
`12:05:55
`
`Dr. Ghosh interprets his data.
`
`I do have a comment
`
`12:05:59
`
`on how other scientists would interpret the
`
`12:06:03
`
`significance of the data and whether or not they
`
`12:06:07
`
`would make those statements.
`
`BY MS. ROYZMAN:
`
`12:06:08
`
`12:06:10
`
`Q.
`
`Okay. Ghosh 1998 doesn't disclose a
`
`12:06:10
`
`solvate of darunavir; correct?
`
`MS. BRODY: Objection to the form.
`
`BY THE WITNESS:
`
`12:06:15
`
`12:06:17
`
`12:06:18
`
`A.
`
`I don't know.
`
`I haven't looked for a
`
`12:06:18
`
`solvate. As far as I know it doesn't, but I would
`
`12:06:21
`
`have to look in detail.
`
`BY MS. ROYZMAN:
`
`12:06:25
`
`12:06:26
`
`Q. Well, you can take your time.
`
`12:06:27
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`212-267-6868
`
`wWw.VeriteXt.com
`
`516-608-2400
`
`VERITEXT REPORTING COMPANY
`
`Janssen Ex. 2045
`
`Lupin Ltd. v. Janssen Sciences Ireland UC
`|PR2015-01030
`
`(Page 9 of 11)
`
`

`
`A.
`
`Hmm?
`
`Q.
`
`A.
`
`You can take your time.
`
`Thank you.
`
`Page 135
`
`12:06:28
`
`12:06:32
`
`12:06:47
`
`He doesn't give the sort of
`
`12:06:48
`
`analytical data that would allow to you decide
`
`12:06:49
`
`whether or not there was a solvate or not.
`
`12:06:51
`
`Q.
`
`And Ghosh 1998 doesn't provide any
`
`12:06:55
`
`crystallization conditions for darunavir; correct?
`
`12:06:58
`
`A.
`
`Not in this ——
`
`MS. BRODY: Objection to the form.
`
`BY THE WITNESS:
`
`A.
`
`Not in this paper that I —— no.
`
`BY MS. ROYZMAN:
`
`12:07:01
`
`12:07:02
`
`12:07:03
`
`12:07:03
`
`12:07:07
`
`Q.
`
`And it's correct that he doesn't provide
`
`12:07:07
`
`any crystallization conditions for darunavir; right?
`
`12:07:10
`
`A.
`
`There's nothing in ——
`
`12:07:14
`
`MS. BRODY: Objection to the form and to the
`
`12:07:15
`
`extent it's outside the scope of this expert's
`
`12:07:16
`
`opinions.
`
`BY THE WITNESS:
`
`12:07:20
`
`12:07:21
`
`A.
`
`You know, that's what's in the paper.
`
`12:07:21
`
`What's in the paper is what's in the paper.
`
`I
`
`12:07:22
`
`wouldn't disagree with that —— your statement.
`
`12:07:24
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`212-267-6868
`
`wWw.VeriteXt.com
`
`516-608-2400
`
`VERITEXT REPORTING COMPANY
`
`Janssen Ex. 2045
`
`Lupin Ltd. v. Janssen Sciences Ireland UC
`|PR2015-01030
`
`(Page 10 of 11)
`
`

`
`BY MS. ROYZMAN:
`
`Page 136
`
`12:07:27
`
`Q.
`
`Okay. And Ghosh 1998 doesn't provide any
`
`12:07:28
`
`data against mutant HIV virus; is that right?
`
`12:07:32
`
`MS. BRODY: Objection to the form and to the
`
`12:07:36
`
`extent it's outside the scope of this witness's
`
`12:07:37
`
`opinions.
`
`BY THE WITNESS:
`
`12:07:40
`
`12:07:40
`
`A.
`
`You know,
`
`I don't know what you want me
`
`12:07:42
`
`to answer.
`
`The paper is the paper.
`
`BY MS. ROYZMAN:
`
`12:07:43
`
`12:07:45
`
`Q. Well, does the paper contain any data
`
`12:07:46
`
`against mutant HIV virus?
`
`12:07:48
`
`A.
`
`Not that I found. Did you find any?
`
`12:07:50
`
`BY MS. ROYZMAN:
`
`Q.
`
`I didn't.
`
`A. Well, good.
`
`Q.
`
`So we're in agreement?
`
`12:07:53
`
`12:07:53
`
`12:07:54
`
`12:07:55
`
`A. Well,
`
`there are lots of things for which
`
`12:07:56
`
`are not in this paper. Are we going to go over them
`
`12:07:59
`
`all?
`
`12:08:01
`
`Q.
`
`I'd like to turn your attention ——
`
`12:08:04
`
`MS. BRODY: You know what.
`
`I mean we've been
`
`12:08:06
`
`going well over an hour and a half now.
`
`I —— just ——
`
`12:08:07
`
`it's a bit unfair to the witness.
`
`12:08:10
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`212-267-6868
`
`wWw.VeriteXt.com
`
`516-608-2400
`
`VERITEXT REPORTING COMPANY
`
`Janssen Ex. 2045
`
`Lupin Ltd. v. Janssen Sciences Ireland UC
`|PR2015-01030
`
`(Page 11 of 11)

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket